Phaseline

Companies › RyCarma Therapeutics

RyCarma Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Surlorian (ARM210, S48168)
Ryanodine receptor 1 (RYR1) activator
RYR1Phase 2Autosomal Dominant RYR1-Related MyopathyAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07560020Surlorian (ARM210, S48168)Phase 2Autosomal Dominant RYR1-Related MyopathyNeurologyAug 2027

Targets

RYR1 (1)

Companies with the same targets

–

Companies built like this

Dasher Neuroscience ThromBio Appello Pharmaceuticals PhenoNet Glycomine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.